Navigation Links
Omeros Reports Allowance of Additional Patent for Arthroscopic Product
Date:5/24/2011

nificantly greater efficacy than vehicle as measured by patient-reported functional scores using the Knee Injury and Osteoarthritis Outcome Score (KOOS), passive knee flexion and visual analog scale pain scores. The patient-reported outcomes measuring symptoms, pain, activities of daily living, sport and recreational activities and quality of life associated with the operated knee showed a sustained benefit through postoperative Day 90.

In the first quarter of 2011, Omeros announced that OMS103HP failed to meet pre-specified efficacy endpoints in a Phase 3 clinical program in patients undergoing arthroscopic anterior cruciate ligament (ACL) reconstruction surgery. Omeros is unable to draw any conclusions about OMS103HP's effect in the Phase 3 ACL program due to confounding factors, and the Company has no plans to conduct additional ACL reconstruction trials at this time. The primary endpoint for Omeros' meniscectomy Phase 3 trials is different than that used in its ACL program. Accordingly, Omeros believes that the results of its ACL program do not affect the viability of its meniscectomy program.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, bleeding and
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros Announces Clinical Development Programs for OMS103HP and OMS302
2. Omeros Corporation Reports First Quarter 2011 Financial Results
3. Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors
4. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
5. Omeros Reports Outcome of Phase 3 Trials of OMS103HP
6. Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results
7. Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders
8. Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo
9. Omeros Announces Publication of Data From Antifibrinolytic Program
10. Omeros Licenses Novel Antifibrinolytic Agents
11. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) released ... care leaders and a new study analyzing the impact of increased ... a nationwide coalition working to educate policy makers and the public ... Capitol was focused on how the Iowa ...
(Date:1/23/2015)... Fla. and DUBLIN , Jan. ... the agreement with KRS Global Biotechnology, Inc. for the compounding, ... be compounded for shipment in the United States ... FDA approved Outsourcing Facility capable of compounding naltrexone tablets in ...
(Date:1/23/2015)... , Jan. 23, 2015  iMD Companies, Inc. (ICBU) has ... increase market share and grab a foothold in the hydroponic, ... production capabilities and a presence in the sector, and recently ... the growth of hemp and medical marijuana, iMD is committing ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... , WILMINGTON, Del., Dec. 8 AstraZeneca (NYSE: ... Medicare Part D prescription savings program will no longer pay ... http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) , Prescriptions also now will ... changes to the AZ&Me(TM) Prescription Savings program for people with ...
... , PITTSBURGH, Dec. 8 Mylan Inc. (Nasdaq: ... has entered into settlement and license agreements with Wyeth, now ... (ER) Capsules, 37.5 mg, 75 mg and 150 mg, the ... major depressive disorder. , Pursuant to the license agreement, Mylan ...
Cached Medicine Technology:AstraZeneca Medicare Part D Patient Assistance Program No Longer Requires Co-Pays 2Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R) 2
(Date:1/22/2015)... a seasoned and trusted leader who consistently delivers trendy dresses ... it lead the wedding dress industry into the future. Today, ... the global market. , “The CEO of VogueQueen is uniquely ... continuing the goal of operational excellence and giving back to ...
(Date:1/22/2015)... 23, 2015 Angelweddingdress is a famous wedding ... its customers to follow it on Facebook, Twitter, and Pinterest. ... Day gift. Angelweddingdress draws a lottery every week. , Moreover, ... Feb. 28, 2015. Click Angelweddingdress homepage for more ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has ... View website of AngelWeddingDress.com to find more ... dresses online for a bridal party. AngelWeddingDress offers a ... them. Its maternity wedding dresses are specially designed for ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and ... Merchandise Show to bestow a Juvent Sports Achievement award ... Arlene McKitrick. The award commemorated and congratulated McKitrick for ... She won her first amateur tournament in 1979 and ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... MAY 28 Family Health International announced today that ... from the Bill & Melinda Gates Foundation. The ... led by David C. Sokal, M.D., studying a novel ... Sokal,s project is one of 81 grants announced by ...
... Identify Developmental Delays and Promote GrowthNEW ORLEANS, May 28 ... - 11:30am , at 1315 Jefferson Highway , ... "Reach Out and Read " with Louisiana,s First Lady ... program. In this initiative, pediatricians encourage parents to read ...
... with a terminal illness, African-American seniors were two times ... life-prolonging treatments, according to a University of Pittsburgh study ... the Journal of General Internal Medicine . ... M.P.H., associate professor of medical, clinical and translational science ...
... owned subsidiary of sanofi-aventis U.S. LLC, has agreed to pay ... violated the False Claims Act by misreporting drug prices in ... Department announced today. ... that between 1995 and 2000, Aventis and its corporate predecessors ...
... Public/Private Partnership Launches at State Legislative Hearing TRENTON, N.J., ... that could cause grave harm to patient care in ... New Jersey Chamber of Commerce Foundation today announced a ... will have the nursing workforce it needs to meet ...
... Kyowa Hakko U.S.A., Inc. (Kyowa Hakko USA), the wholly ... has announced it has completed GRAS (Generally Recognized As ... Citicoline. Cognizin(R) is a branded form of Citicoline, a ... Citicoline provides an essential nutrient for cells -- ...
Cached Medicine News:Health News:Family Health International Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research Project Led by David Sokal, M.D. 2Health News:Family Health International Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research Project Led by David Sokal, M.D. 3Health News:Family Health International Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research Project Led by David Sokal, M.D. 4Health News:Ochsner Introduces Literacy Program to Promote Healthy Minds 2Health News:Blacks more likely to opt for life-sustaining measures at end of life 2Health News:Aventis Pharmaceutical to Pay U.S. $95.5 Million to Settle False Claims Act Allegations 2Health News:$22 Million Initiative Aims to Reverse New Jersey's Nurse Faculty Shortage, Avert Health Care Crisis 2Health News:$22 Million Initiative Aims to Reverse New Jersey's Nurse Faculty Shortage, Avert Health Care Crisis 3Health News:$22 Million Initiative Aims to Reverse New Jersey's Nurse Faculty Shortage, Avert Health Care Crisis 4Health News:$22 Million Initiative Aims to Reverse New Jersey's Nurse Faculty Shortage, Avert Health Care Crisis 5Health News:Kyowa Hakko USA Announces GRAS Self-Affirmation for Novel Brain Health Ingredient Cognizin(R) Citicoline 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: